Mike Hollan

Farbman discusses the struggles that pharma companies are facing when trying to raise funds and how this is impacting IPOs.

Powley discusses his team’s recent patient journey mapping exercise and the impact it has had on RMMH.

Orne discusses the forces impacting the life sciences market and how companies are reacting.

Heidmann discusses the difficulties of enrolling patients in clinical trials and the ways these issues can be dealt with.

Leuchter discusses FDA’s new pilot program.

Smalley discusses her work with proactive signal detection.

Ho discusses how gamma-delta T cells can improve cancer treatments.

Shields discusses Ferring’s recent $5 million endowment to the American Society of Reproductive Medicine.

McCullar discusses his new role as CEO of RegCell.

There is no cure for having to remember countless logins/passwords.

Solomon discusses new ways that researchers are fighting against bacterial resistance to medications.

Mangal discusses the causes of the shortage and how pharma companies can find solutions.

Raja discusses how the pharma industry can improve its ecological impact.

Schmidt discusses the recent announcement that Medidata and the NCI extended their partnership an additional five years.

Stark discusses pharma’s supply chain and the issues it is facing.

Ito discusses how data-driven AI can be utilized by the pharma industry.

Cunningham discusses the obstacles to raising funds in the current climate.

Morton discusses his transition from working as a urologist to the C-suite.

Gill discusses her continuing work to transform clinical trials and improve the patient experience through DCTs.

Industry experts discuss the relationship between digital and traditional (key) opinion leaders and how companies are adjusting their strategies to harness the unique brand engagement benefits each role can provide in driving better patient outcomes.

A discussion of the impact the new FDA SaMD guidance, identifying the differences between companion apps and SaMD, and what to expect from this combination in the future.

Klein discusses how recent FDA draft guidelines will impact the use of SaMD in the life sciences industry.

Chandler discusses how life sciences companies are navigating the current climate.

Kirsch discusses the complexity of the drugs and the verification process, along with EVERSANA’s new platform, ACTICS eAccess.

Rubin speaks about how drugs aren’t being properly valued.

Lakdawalla speaks about how drugs aren’t being properly valued.

Accenture’s global life sciences technology lead discusses how the life sciences industry has embraced artificial intelligence.

Cleve talks about the future of the industry and how data remains a key focus.

Early success ignites promise in reshaping standards of care for HER2 breast cancer.